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ABSTRACT 
Background  
Matrix-metalloproteinases (MMPs) are proteolytic enzymes that can degrade the extra cellular matrix 
and drive tissue remodelling, key processes in the pathogenesis of COPD.  The development of small 
airway disease has been identified as a critical mechanism in the early development of airflow 
obstruction but the contribution of MMPs in human disease is poorly characterised. 
 
Objectives  
We investigated the role of MMPs and inflammatory cytokines in the lung by quantifying levels and 
determining relationships with the key pathological components of COPD in patients and healthy 
controls.  
Methods  
We analysed levels of MMPs and inflammatory cytokines in bronchoalveolar lavage (BAL) from 24 
COPD and 8 control subjects. Each subject underwent spirometry and High Resolution CT. Image 
analysis quantitatively assessed emphysema, bronchial wall thickening and small airways disease.  
 
Results 
Multiple MMPs (MMP-1, -2, -3, -8, -9 and -10) and cytokines (IL-6 and IL-8) were elevated in COPD 
subjects’ lungs. MMP -3, -7, -8, -9, -10, and -12 concentrations closely associated with CT markers of 
small airways disease. Emphysema severity was also associated with MMP-3, -7 and -10. However 
there were no strong relationships between MMPs and bronchial wall thickness of the larger airways. 
 
Conclusion  
Pulmonary MMP concentrations are directly associated with the extent of gas trapping and small 
airways disease identified on CT scan. This study suggests that MMPs play a significant role in small 
airways remodelling, a key feature in the pathogenesis of COPD. 
 
Trial registration number NCT01701869 
Word Count 234 
  
KEY MESSAGES 
What is the key question? 
Are MMPs involved in the development of pathological changes in the lung of patients with COPD 
and what is their association with emphysema formation, bronchial wall thickening and small 
airways remodelling?  
What is the bottom line? 
Bronchoalveolar lavage concentrations of multiple MMPs are increased in COPD patients and these 
are associated with the degree of small airways disease and emphysema measured by CT analysis. 
Why read on? 
This study combines quantitative CT analysis with multiplex profiling of MMPs and inflammatory 
mediators to identify a new role of proteases in COPD.  
  
INTRODUCTION 
COPD is a heterogeneous disease characterised by the progressive development of airflow limitation 
which leads to functional impairment and associated symptoms1. The underlying mechanisms of 
disease are poorly understood, which has limited the development of new therapeutic and diagnostic 
approaches2. 
Tissue destruction, inflammation and airway remodelling are important features in COPD and a 
number of pathways and mediators have been implicated in these processes3. A 
proteinase/antiproteinase imbalance has been postulated to be a key contributor to emphysematous 
changes4. Matrix metalloproteinases (MMPs), a large family of zinc-dependent proteolytic enzymes, 
have the ability to degrade the pulmonary extracellular matrix (ECM) and have been implicated in 
COPD4. They are broadly grouped depending on their substrate specificity, including collagenases 
(MMP-1, -8 and -13), gelatinases (MMP-2 and -9), stromelysins (MMP-3, -10 and -11) and elastases 
(MMP-7 and -12)5, although there is considerable substrate overlap. MMPs are not normally 
expressed in healthy tissue but in disease can be produced by alveolar macrophages, neutrophils and 
bronchial epithelial cells5. They are tightly regulated by specific endogenous inhibitors, the four Tissue 
inhibitors of MMPs (TIMP)5. 
 
Transgenic mice over expressing MMP-1 develop emphysema at an accelerated rate6. Selective 
inhibition of MMP-9 and -12 in guinea pigs reduced the extent of emphysema following  exposure to 
smoke7. Human studies demonstrate increased expression of MMP-18,9, -89,10, -98–13 and -128,14,15 in 
the sputum or bronchoalveolar lavage (BAL) of COPD subjects. However, detailed analysis of the MMP 
profile has not been integrated with systematic characterisation of lung pathology by high resolution 
computed tomography (HRCT) and lung function. 
MMPs have complex biology with multi-step activation and numerous molecular interactions16, and 
the most important MMPs have yet to be determined in COPD. In addition, MMPs have multiple other 
functions that are independent of their ability to degrade the ECM, including facilitating cell migration 
and activating growth factors and cytokines5. Most studies investigating MMPs in COPD have only 
investigated a subset of MMPs. Given their biological complexity, novel multiplex-based arrays 
provide the opportunity to profile a broad spectrum of MMPs in a carefully characterised clinical 
cohort.   
 
The key sites of MMP activity in the lung are unknown and it is likely that matrix turnover and 
remodelling differs between regions. CT imaging provides the opportunity to study key morphological 
features of COPD including emphysema, bronchial wall morphology and small airways disease. 
Quantitative analysis software allows numerical, objective estimation of these disease facets17. MMP-
9 and -12 have been shown to have associations with quantitative measures of emphysematous 
change on CT11,14. Previous studies have not investigated the association between MMP 
concentrations and bronchial wall measures or small airways disease identified by CT. In this study, 
we combine CT analysis of lung pathology with multiplex profiling of MMPs and inflammatory 
mediators, and identify a novel role for MMPs in COPD.  
 
METHODS 
Subjects 
Subjects gave written informed consent and the study (ClinicalTrials.gov:NCT01701869) was approved 
by the South Central - Southampton B NRES Committee (12/SC/0304).  
Twenty-four subjects with stable mild and moderate COPD as defined by GOLD guidelines1 were 
recruited into the study. Post-bronchodilator spirometry was used to assess airflow obstruction with 
a FEV1/FVC ratio of <0.7 and an FEV1 of ≥50% predicted value required for enrolment. Spirometry was 
conducted in accordance with American Thoracic Society standards18. Subjects had at least a smoking 
history of 10 pack years. Exclusion criteria included a history of other pulmonary disease, alpha-1-
antitrypsin deficiency, long-term antibiotics/steroids or an exacerbation within the month prior to 
recruitment. A control group of eight current or ex-smokers, with at least a 10 pack year history but 
preserved lung function were also recruited.  
CT Scanning and Quantitative Image Analysis 
Subjects underwent volumetric CT scans of the chest using a Siemens Sensation 64 CT scanner. The 
imaging protocol consisted of; slice thickness 0.75mm, slice separation 0.5mm, tube voltage 120KV, 
effective mAs 90mAs (using dose modulation), collimation 0.6mm and a pitch of 1. Subjects were 
scanned at full inspiration. A sub-cohort of 22 subjects were scanned at end-tidal volume. The 
remaining did not have an expiratory scan due to concerns over cumulative radiation exposure having 
had recent CT scans.  
Images reconstructed with the B35 kernel were used for image analysis using Apollo Software (VIDA 
Diagnostics). Emphysema was quantified by the percent of lung voxels on the inspiratory scan with 
attenuation values below -950HU (%LAA). Bronchial wall thickening was quantified using the 
standardised parameter Pi10, which is the square root of the wall area of a hypothetical airway with 
a 10mm internal perimeter. A surrogate marker for small airways disease was measured using the 
ratio of mean lung attenuation on expiratory and inspiratory scans (E/I MLD), which has been 
previously validated19.  
Bronchoscopy and Sample Acquisition 
Fibreoptic bronchoscopy was performed on an outpatient basis. In each subject two lobes were 
targeted and BAL was performed by instilling 100ml of 0.9% saline into each lobe and recovered by 
aspiration. BAL fluid was poured through 100µm filters and cells removed by 400g centrifugation for 
10 minutes at 4⁰C. The supernatant was aliquoted and stored at -80⁰C prior to analysis.  The resulting 
cell pellets were prepared for cytospin analysis as previously described20. 
MMP and cytokine analysis 
MMP and cytokine concentrations in BAL were quantitated using a microparticle based multiplex 
immunoassay (R&D systems, Abingdon, UK) developed by Luminex corp. Samples were analysed on 
the Luminex 200 platform (Biorad Bioplex 200, Hemel Hempstead, UK), as per manufacturer’s 
instructions. The following MMPs were analysed: MMP-1, -2, -3, -7, -8, -9, -10, -12 -13 and extracellular 
matrix metalloproteinase inducer (EMMPRIN), a cell surface molecule that can be shed. TIMP 1-4 were 
analysed and cytokine analysis was performed for IL-1β, IL-2, IL-6, IL-8, IL-10, GM-CSF, IFNγ and TNFα. 
(See Supplementary data for assay sensitivities). 
Statistical Analysis 
Statistical analyses were performed using SPSS version 21. Mann-Whitney U test and Fisher’s exact 
tests compared data between COPD and control groups. In the COPD subjects, associations between 
MMPs, spirometry, CT parameters and cytokines were assessed using Spearman’s correlation with rho 
and p values presented. Partial Spearman’s correlation was used to conduct multivariate analysis. Each 
subject had two lobes sampled and the mean concentrations between the lobes were used. For the 
purpose of statistical analysis, values that were below the lower limit of detection were given the 
value of half the concentration of detection. A p-value of <0.05 was considered statistically significant.  
 
  
RESULTS 
Subject Characteristics 
COPD and control groups were well matched for age, sex and current smoking status (Table 1). There 
were more males in both groups. FEV1% and FEF75-25% were significantly lower in the COPD group.  
 
Table 1 Characteristics of participants included in the study 
 COPD (n=24) Controls (n=8) P value 
Age 66.0 (12.0) 56.0 (18.0) 0.064 
Male 16 6 >0.999 
Current smoker 11 5 0.685 
FEV1% 69.00 (21.00) 108.00 (20.25) <0.001* 
FEV1/FVC 54.50 (10.75) 78.00 (9.50) <0.001* 
FEF75-25% 21.50 (16.0) 77.50 (45.25) <0.001* 
Emphysema % (%LAA) 8.24 (7.17) 2.55 (3.35) 0.029* 
Bronchial wall area (Pi10) 3.74 (0.15) 3.74 (0.04) 0.502 
Small airways disease  
(E/I MLD) 
0.86 (0.08) 0.76 (0.10) 0.002* 
Values are given as medians (IQR). 
Male and current smokers given as number of subjects. 
%LAA and Pi10 given for 31 subjects. The ratio of mean lung density in expiration to inspiration (E/I 
MLD) is given for a sub-cohort of 22 subjects who had expiratory CT scans.  
*p<0.05. Fisher’s exact test for male and current smoker. Mann-Whitney U-test for all other 
variables. 
  
 
MMP Concentrations in COPD and Controls 
Median MMP-1, -2, -3, -8, -9 and -10 were significantly higher in the BAL of COPD subjects compared 
to controls (Figure 1). There was no significant difference in MMP-7, -12, -13 and EMMPRIN between 
the groups.   
 
Neutrophil and Cytokine Concentrations in COPD and controls 
BAL neutrophil count, IL-6 and IL-8 concentrations were significantly higher in COPD subjects than 
controls (Figure 2). There were no significant differences in IL-1β and GM-CSF between groups. IL-2, 
IL-10, IFNγ and TNF-α were only detected at very low concentration in all samples and so further 
analysis was not performed.   
 
Associations between MMPs, cytokines, lung function and CT parameters 
We investigated the relationships between MMPs, cytokines and physiological and CT parameters in 
the COPD subjects.  
 
Relationships of MMPs with cytokines and neutrophils 
We performed a systematic analysis of associations between cytokines, neutrophils and tissue-
destructive MMPs, using Spearman’s correlation.  There were significant associations between the 
cytokines IL-6 and IL-8 and MMP-1, -7, -8, -9, -12 and EMMPRIN (Table2).  GM-CSF was associated with 
MMP-8, -9 and EMMPRIN. IL-1β had a negative correlation with MMP-3 while neutrophil counts were 
not associated with any MMPS. 
 
 
Table 2 Spearman’s correlation analysis between MMPs, spirometry, CT measures of disease and 
cytokines and neutrophils in COPD subjects  
 MMP-1 MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-10 MMP-12 MMP-13 EMMPRIN 
Cytokines and neutrophils  
IL-1β  0.26 -0.20 -0.44* 0.08 0.30 0.21 -0.21 -0.00 0.18 0.22 
IL-6 0.51* -0.18 0.28 0.55** 0.69*** 0.55** 0.21 0.52** -0.22 0.54** 
IL-8 0.44* -0.26 0.06 0.53** 0.90*** 0.78*** 0.16 0.56** -0.01 0.46* 
GM-CSF -0.02 -0.16 -0.25 0.15 0.41* 0.41* 0.13 0.20 -0.31 0.68*** 
Neutrophils -0.12 0.07 0.44 0.40 0.41 0.28 0.25 0.29 -0.26 0.36 
Spirometry 
FEV1% -0.35 0.28 -0.34 -0.35 -0.60** -0.59** -0.19 -0.51* 0.02 -0.20 
FEF75-25% -0.47* 0.39 -0.03 -0.18 -0.61** -0.58** -0.11 -0.44* 0.22 -0.22 
CT Parameters 
Emphysema % 
(LAA%) 
-0.03 -0.05 0.49* 0.52** 0.35 0.33 0.52* 0.09 -0.24 0.14 
Small airways 
Disease 
(E/I MLD) 
0.16 -0.14 0.52* 0.52* 0.60* 0.56* 0.55* 0.50* -0.03 0.32 
Bronchial wall area 
(Pi10) 
0.12 0.08 0.04 0.11 0.23 0.21 0.13 0.17 0.20 0.15 
Spearman’s rho values given.  
N=24, apart from associations with E/I MLD (n=16) 
* p<0.05 **p<0.01 ***p<0.001 
 
 
Relationships of MMPs, cytokines, neutrophils with lung function  
We compared MMP and cytokine concentrations with lung function markers of disease severity using 
Spearman’s correlation. There were significant associations between airflow obstruction (FEV1%) and 
MMP-8, -9 and -12 and between FEF75-25% and MMP-1, -8, -9, and -12 (Table 2). MMP-8 had the 
strongest association with both FEV1% and FEF75-25% (Figure 3) and using partial correlation this 
remained significant when adjusting for each of the other MMPs in turn apart from MMP-9 
(Supplementary Table 1).   
 
FEV1% and FEF75-25% were significantly associated with IL-8. FEF75-25% was also associated with IL1-
β. There was no association between these spirometric markers and BAL neutrophils, IL-6 and GMCSF 
(supplementary Table 2).    
 
CT Analysis 
Quantitative CT analysis was performed to study emphysema, bronchial wall morphology and small 
airways disease and assess the relationships with MMPS and cytokines. Segmentation and 
quantitative analysis was successfully achieved in 31 subjects. One of the control CT scans could not 
be analysed for technical reasons.  
Emphysema  
Subjects with COPD had significantly more emphysema (higher %LAA) than controls (Table 1), 
although there was no significant association between emphysema and FEV1% in the COPD subjects 
(rho -0.10, p 0.63).  
There were significant associations between emphysema (%LAA) and MMP-3, -7, and -10 (Table 2). 
MMP-10 had the strongest association with emphysema (Figure 3) and using partial correlation this 
remained significant when adjusting for each of the other MMPs apart from MMP-3 and -7 
(Supplementary Table 1). Emphysema was not associated with neutrophils or cytokines 
(Supplementary Table 2).   
 
Small Airways Disease 
Small airways disease (E/I MLD) was greater in the COPD group than controls (Table 1). Strong 
associations with FEV1% (rho -0.72, p 0.002) and FEF75-25% (rho -0.54 p 0.03) were seen in COPD 
subjects.  
 
There were associations between small airways disease (E/I MLD) and MMP-3, -7, -8, -9, -10 and -12 
(Table 2). MMP-8 had the strongest association with small airways disease (Figure 3) and this remained 
significant after adjusting for MMP-1, -2 and -13 in turn but not the other MMPs (Supplementary Table 
1). The only cytokine that correlated with small airways disease was IL-8 (Supplementary Table 2).  
Bronchial Wall Thickening 
There was no significant difference in bronchial wall thickening (Pi10) between COPD and controls but 
there was an association between Pi10 and FEV1% in COPD subjects (rho -0.59, p 0.003). There were 
no associations between airway wall area and MMPs (Table 2). Neutrophils and cytokines did not show 
any association with bronchial wall area (Supplementary Table 2).  
 
 
 
 
 
 
 
 
 
 
  
DISCUSSION 
This study has, for the first time, demonstrated an association between small airways disease 
measured by CT imaging and the lung concentrations of MMPs and inflammatory cytokines in COPD. 
MMPs and cytokines are also associated with other markers of disease severity, including FEV1% and 
emphysema severity. The analysis suggests that associations were stronger between MMPs and small 
airways disease rather than emphysema.  
MMPs are structurally similar proteolytic enzymes that have been implicated in the tissue remodelling, 
matrix destruction and inflammation seen in COPD4. We found that MMP-1, -2, -3, -8, -9 and -10 were 
elevated in the airways of COPD subjects.  This is in keeping with previous studies which demonstrated 
that MMP-18,9, -89,10 and -98–13 are increased in COPD subjects. Furthermore, we have also shown that 
MMP-2, -3 and -10 were increased. A histological study of lung resection subjects also found that 
MMP-2 was up-regulated in the lung periphery in COPD21. However, Culpitt et al found no difference 
between MMP-2 and -3 in sputum between COPD and controls9. Our results may diverge from these 
due to the difference in sampling locations between sputum and BAL.  Previous studies also found 
that MMP-12 is increased in COPD8,14,15, although we did not replicate this observation in our cohort. 
We analysed the ratio of MMPs: TIMPs and found they were significantly increased in COPD subjects 
(data not shown) and this was especially the case for MMP-8 and MMP-10. This supports the idea of 
a proteinase to antiproteinase imbalance, however further work is required to understand this fully. 
We also found the concentrations of neutrophils, IL-6 and IL-8 were increased in COPD, which is 
consistent with previous work22. This provides further evidence for the role of neutrophilic airway 
inflammation in COPD.   
Most work to date has focused on assessing the role of MMPs in emphysema. Transgenic mice 
overexpressing MMP-1 develop emphysema at an accelerated rate6. MMP-12 knockout mice are 
protected from cigarette induced lung damage23. In the SMAD3 mouse model of emphysema, genetic 
blockade of MMP-9 reduced the amount of emphysema24. Selective inhibition of MMP-9 and -12 in 
guinea pigs reduced the extent of emphysema when exposed to smoke7. In human genetic studies, 
polymorphisms of MMP-9 genes have been linked to emphysematous change25,26 while 
polymorphisms of MMP-12 have been linked to airflow obstruction27. Previous work using lavage fluid 
found that MMP-1, -9 and -12 were significantly raised in emphysematous patients when compared 
to healthy non-smokers but not current smokers8. In two studies using quantitative CT analysis the 
LAA% correlated with sputum MMP-9 and -1211,14. Unlike these two studies, we did not find any 
associations between CT-measured emphysema and MMP -9 or -12, which may be due to the 
differences between sampling sputum or BAL. However, we found significant associations between 
quantified emphysema and MMP-3, -7 and -10, which have not been previously investigated. MMP-
10 had the strongest association with emphysema and interestingly this and the other significantly 
associated MMPs have limited elastin degradation properties and mainly degrade collagens and 
proteoglycans. Studies show there is actually increased collagen around emphysematous lesions28 and 
therefore a key mechanism may be MMP-induced collagen breakdown and subsequent abnormal 
remodelling and aberrant deposition of collagen.   
We measured bronchial wall thickening of larger airways using the standardised marker Pi10 which 
has been shown to correlate with FEV1%29 and is elevated in COPD30. Our analysis found no significant 
difference in Pi10 between COPD and controls but did show an association with airflow obstruction. 
There were no significant associations between Pi10 and MMPs or inflammatory cytokines. The 
reasons for this are unknown but it may be that Pi10 is not the best measure at assessing airway wall 
morphology. It is also feasible that bronchial wall thickening is not directly linked to luminal 
inflammatory indices or protease activity and the remodelling response in the proximal airway may 
be more related to inflammatory infiltration of the submucosa31 and biopsy studies may be required 
to elicit these mechanisms. 
Small airways disease is a key feature of COPD and has been identified as the main site of the airflow 
obstruction seen in the disease32. Histopathological studies have identified that the small airways are 
thickened and morphologically abnormal with a combination of squamous cell metaplasia, goblet cell 
hyperplasia and peri-bronchial fibrosis apparent33. There is currently no gold standard for investigating 
and assessing small airways disease in COPD. CT lacks the resolution to image the small airways 
directly, however the indirect sign of gas trapping can be used17.  A number of quantitative CT methods 
exist to measure this and we chose to use the ratio of mean lung density in expiration against 
inspiration. Hersh et al confirmed that E/I MLD had a good correlation with lung function markers of 
small airways disease34. Bommart also demonstrated that E/I MLD was the best CT marker of gas 
trapping as measured by nitrogen washout19. We found E/I MLD was significantly raised in COPD and 
had strong associations with FEV1% and FEF75-25%, supporting its use as a marker of small airway 
disease.  
Few studies have investigated the role of MMPs in small airways disease. In guinea pigs, inhibition of 
MMP-9 and -12 protected the animals from small airways fibrosis in response to cigarette smoke 
exposure7. A study of symptomatic smokers with normal lung function found that MMP-8, -9 and -12 
in induced sputum correlated with FEF75-2535. Our results found that MMP-1, -8, -9, and -12 had 
associations with FEF75-25%. However this is an insensitive and non-specific marker of small airways 
disease. When using the CT marker E/I MLD we found strong associations with the concentrations of 
MMP-3, -7, -8, -9, -10 and -12. These associations tended to be stronger than those seen with 
emphysema, suggesting that MMPs may play a significant role in the development of small airway 
remodelling and the associated airflow obstruction. MMP-8 had the strongest association with small 
airways disease and along with the other associated MMPS are mainly produced by neutrophils and 
macrophages and between them are able to degrade all components of the ECM. In the small airways 
it has been demonstrated that elastin and collagen are reduced in COPD patients36 and we propose 
this degradation is driven by MMPs leading to deranged remodelling and fibrosis. 
We recognise that the main limitation of this study was the small sample size and associated limited 
statistical power, meaning we were unable to analyse certain aetiological factors such as smoking. 
However every effort was made to phenotype our cohort with CT imaging and invasive bronchoscopy 
techniques. Despite this we found strong evidence of the associations between MMPs and clinical 
features of disease. Another limitation is the multiple comparisons made in this study. We tested 129 
associations between parameters of physiology, CT indices and laboratory markers. At the 5% level 
around 7 associations would be expected to be significant just by chance. We found 38 significant 
associations, far higher than the number expected by chance, suggesting the presence of genuine 
associations.  Due to the need to perform bronchoscopy, our study consisted of mild and moderate 
COPD patients, with only limited amounts of emphysema. It is unknown whether these results would 
be the same in more severe patients. In this study we measured concentrations of MMPs rather than 
MMP activity. Lowrey demonstrated that although MMP-9 concentrations were increased in the 
sputum of COPD subjects MMP-9 activity was not12.  However due to the site and nature of action of 
MMPs there is considerable debate as to whether concentrations or activity assays best reflect the 
action of MMPs37. Another limitation was that only a sub-cohort of 16 COPD subjects had both an 
inspiratory and expiratory CT scan, allowing assessment of small airways disease. Repeating 
emphysema and airflow analysis on this subsample yielded broadly similar results, indicating the 
smaller sample size did not influence the results.   
In conclusion, multiple MMPS are increased in the airways of subjects with COPD and are associated 
with the severity of airflow obstruction and quantitative CT measures of emphysema and small 
airways disease. This suggests that MMPs may play a significant role in the pathogenesis of COPD by 
causing breakdown of the pulmonary ECM leading to abnormal remodelling in both the small airways 
and lung parenchyma. Further work is required to investigate these important mechanisms and to 
understand the heterogeneity of the disease within different compartments of the lung. Whilst most 
previous work has focused on MMPs and emphysema this study suggests the strongest associations 
were with small airways disease. Interventions directed at inhibiting MMPs may have a role in 
preventing small airways remodelling and any trial investigating modulation of MMPs should utilise 
CT analysis as a marker of small airways disease.  
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FIGURES 
 
 
Figure 1 – BAL expression of MMPs in COPD and controls (HC). (A) MMP-1 (B) MMP-2 (C) MMP-3 (D) 
MMP-7 (E) MMP-8 (F) MMP-9 (G) MMP-10 (H) MMP-12 (I) MMP-13 (J) EMMPRIN. Data represents 
median with IQ range. Each dot represents BAL concentration of individual MMP in a specific patient, 
n=24 for COPD and 8 for controls. * p<0.05 ** p<0.01 ***p<0.001 using Mann-Whitney U test. 
 
 
 Figure 2 – BAL expression neutrophils and cytokines in COPD and controls (HC). (A) differential BAL 
neutrophil count (%) (B) IL-1B (C) IL-6 (D) IL-8 (E) GM-CSF. Data represents median with IQ range. Each 
dot represents BAL concentration of individual value in a specific patient, n=24 for COPD and 8 for 
controls. * p<0.05 **p<0.01 using Mann-Whitney U test. 
 
  
 
Figure 3 – Scatterplots of COPD subjects for (A) log MMP-8 against FEV1% (B) log MMP-8 against log 
FEF75-25% (C) log MMP-10 against LAA% (D) log MMP-8 against E/I MLD. These plots are visualised as 
they represent the MMPs with the strongest associations with the accompanying outcome variable. 
N=24, apart from E/I MLD (n=16).  
 
 
 
 
 
